Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2350-2358

  Zhang, Xun ^a   Gejman, Roger ^a   Mahta, Ali ^a   Zhong, Ying ^a   Rice, Kimberley A ^a   Zhou, Yunli ^a   Cheunsuchon, Pornsuk ^a   Louis, David N ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODEOXYCYTIDINE; MATERNALLY EXPRESSED GENE 3 PROTEIN; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ASSAY; CHROMOSOME 14Q; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SYNTHESIS INHIBITION; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE LOCUS; GENE LOSS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MENINGIOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA GENE; SPINAL ARACHNOID; TRANSACTIVATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ARACHNOID; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA, COMPLEMENTARY; GENE DOSAGE; GENES, TUMOR SUPPRESSOR; GENOMIC IMPRINTING; HUMANS; MENINGIOMA; PROMOTER REGIONS, GENETIC; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950193818     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3885     Document Type: Article

References (50)

1. Louis DN OH, Wiestler OD, Cavenee WK. World Health Organization classification of tumours of the central nervous system. Lyon: IARC Press; 2007.
2. Lusis E, Gutmann DH. Meningioma: an update. Curr Opin Neurol 2004;17:687-692
3. Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995;55:4696-4701
4. Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94:14719-14724
5. Menon AG, Rutter JL, von Sattel JP, et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 1997;14:611-616
6. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 2001;60:628-636
7. Zhang X, Zhou Y, Mehta KR, et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 2003;88:5119-5126
8. Zhou Y, Zhong Y, Wang Y, et al. Activation of p53 by MEG3 noncoding RNA. J Biol Chem 2007;282:24731-24742
9. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab 2005;90:2179-2186
10. Gejman R, Batista DL, Zhong Y, et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2008;93:4119-4125
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-△△ C(T)) method. Methods 2001;25:402-408
12. Senchenko V, Liu J, Braga E, et al. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene 2003;22:2984-2992
13. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X. DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem 2003;278:462-470
14. Zhang X, Sun H, Danila DC, et al. Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 2002;87:1262-1267
15. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 1998;95:521-530
16. Leone PE, Bello MJ, de Campos JM, et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999;18:2231-2239
17. Schneider BF, Shashi V, von Kap-herr C, Golden WL. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis. Cancer Genet Cytogenet 1995;85:101-104
18. Tse JY, Ng HK, Lau KM, Lo KW, Poon WS, Huang DP. Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. Hum Pathol 1997;28:779-785
19. Zang KD. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 1982;6:249-274
20. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci U S A 1987;84:5419-5423
21. Dumanski JP, Carlbom E, Collins VP, Nordenskjold M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Natl Acad Sci U S A 1987;84:9275-9279
22. Casalone R, Simi P, Granata P, et al. Correlation between cytogenetic and histopathological findings in 65 human meningiomas. Cancer Genet Cytogenet 1990;45:237-243
23. Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca EA. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg 1999;91:85-92.
24. Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002;16:1060-1065
25. Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 2008;98:256-262
26. Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC. Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol 2008;87:43-50.
27. Pfisterer WK, Hank NC, Preul MC, et al. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol 2004;6:290-299
28. Sayagues JM, Tabernero MD, Maillo A, et al. Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome-specific probes. Cytometry 2002;50:153-159
29. Miyoshi N, Wagatsuma H, Wakana S, et al. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells 2000;5:211-220
30. Schuster-Gossler K, Simon-Chazottes D, Guenet JL, Zachgo J, Gossler A. Gtl2lacZ, an insertional mutation on mouse chromosome 12 with parental origin-dependent phenotype. Mamm Genome 1996;7:20-24
31. Schmidt JV, Matteson PG, Jones BK, Guan XJ, Tilghman SM. The Dlk1 and Gtl2 genes are linked and reciprocally imprinted. Genes Dev 2000;14:1997-2002.
32. Takada S, Tevendale M, Baker J, et al. Delta-like and gtl2 are reciprocally expressed, differentially methylated linked imprinted genes on mouse chromosome 12. Curr Biol 2000;10:1135-1138
33. Smas CM, Sul HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993;73:725-734
34. Friedrichsen BN, Carlsson C, Moldrup A, et al. Expression, biosynthesis and release of preadipocyte factor-1/delta-like protein/fetal antigen-1 in pancreatic β-cells: possible physiological implications. J Endocrinol 2003;176:257-266
35. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG, Kassem M. Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res 2004;19:841-852
36. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol Histopathol 2000;15:119-129
37. Lee K, Villena JA, Moon YS, et al. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003;111:453-461
38. Charlier C, Segers K, Karim L, et al. The callipyge mutation enhances the expression of coregulated imprinted genes in cis without affecting their imprinting status. Nat Genet 2001;27:367-369
39. Paulsen M, Takada S, Youngson NA, et al. Comparative sequence analysis of the imprinted Dlk1-2 locus in three mammalian species reveals highly conserved genomic elements and refines comparison with the Igf2-19 region. Genome Res 2001;11:2085-2094
40. Takada S, Paulsen M, Tevendale M, et al. Epigenetic analysis of the Dlk1-2 imprinted domain on mouse chromosome 12: implications for imprinting control from comparison with Igf2-19. Hum Mol Genet 2002;11:77-86.
41. Wylie AA, Murphy SK, Orton TC, Jirtle RL. Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. Genome Res 2000;10:1711-1718
42. Astuti D, Latif F, Wagner K, et al. Epigenetic alteration at the DLK1-2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer 2005;92:1574-1580
43. Pantoja C, de Los Rios L, Matheu A, Antequera F, Serrano M. Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res 2005;65:26-33.
44. Yin D, Xie D, Sakajiri S, et al. DLK1: increased expression in gliomas and associated with oncogenic activities. Oncogene 2006;25:1852-1861
45. Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet 2006;15:821-830
46. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
47. Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004;75 Suppl 2:ii2-11.
48. Cho H, Ha SY, Park SH, Park K, Chae YS. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. J Korean Med Sci 1999;14:199-205.
49. Amatya VJ, Takeshima Y, Inai K. Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 2004;17:705-710
50. Schuster-Gossler K, Bilinski P, Sado T, Ferguson-Smith A, Gossler A. The mouse Gtl2 gene is differentially expressed during embryonic development, encodes multiple alternatively spliced transcripts, and may act as an RNA. Dev Dyn 1998;212:214-228